Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
出版年份 2020 全文链接
标题
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
作者
关键词
-
出版物
Cancer Management and Research
Volume Volume 12, Issue -, Pages 3741-3749
出版商
Informa UK Limited
发表日期
2020-05-20
DOI
10.2147/cmar.s202973
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
- (2020) Filippos Koinis et al. Cancers
- Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
- (2019) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN
- (2019) Abdallah Flaifel et al. CLINICAL CANCER RESEARCH
- Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
- (2019) Arpita Desai et al. Future Oncology
- Transcription factor SOX18 promotes clear cell renal cell carcinoma progression and alleviates cabozantinib-mediated inhibitory effects
- (2019) Yin Huaqi et al. MOLECULAR CANCER THERAPEUTICS
- Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
- (2019) Frede Donskov et al. EUROPEAN JOURNAL OF CANCER
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Robert J. Motzer et al. BRITISH JOURNAL OF CANCER
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Advances in studies of tyrosine kinase inhibitors and their acquired resistance
- (2018) Qinlian Jiao et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis
- (2018) Peter Hale et al. Journal of Geriatric Oncology
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
- (2018) Thomas Powles et al. BRITISH JOURNAL OF CANCER
- Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone
- (2017) Kai-Jie Yu et al. Oncotarget
- Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
- (2016) Linh Nguyen et al. ANTI-CANCER DRUGS
- Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
- (2016) Zeynep Firtina Karagonlar et al. CANCER SCIENCE
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
- (2016) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer
- (2015) Y.-C. Lee et al. CANCER RESEARCH
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
- (2015) A. Varkaris et al. CLINICAL CANCER RESEARCH
- Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects
- (2015) Linh Nguyen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Acquired resistance to drugs targeting receptor tyrosine kinases
- (2011) Steven A. Rosenzweig BIOCHEMICAL PHARMACOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started